30 closest matches · ranked by relevance
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.5; 9.9 Months — p=0.0120
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods — 5.6 months
Non-small Cell Lung Cancer
Primary: Overall Survival — 12.55; 13.40 months — p=0.94896
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Non Small Cell Lung Cancer
Primary: Overall Survival Time (OS) — 11.3; 11.5 Months — p=0.9561
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) — 51.0 percentage of…
Non Small Cell Lung Cancer
Primary: Phase 2: Progression-Free Survival Time — 4.7; 1.5 months
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 7.4; 3.8; 4.4 months — p=0.003
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Lung Cancer
Primary: PERCIST Partial Metabolic Response — 6 participants
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) in the ITT (Non-squamous) Population — 376; 379 days — p=0.401
Non-Small Cell Lung Cancer Stage IV
Primary: Progression Free Survival (PFS) — 2.53; 4.21 months — p=0.0068
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants With a Tumor Response (Objective Tumor Response Rate) — 38.5 percentage of participants
Squamous Non-small Cell Lung Cancer
Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB) — 30; 50; 58.8; 30.3 Percent of Participants
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Advanced Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) — 2; 2; 9; 1 Participants
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.95; 6.83 Months — p=0.0618